Fennec Pharmaceuticals, Inc. FENC 深 滬
已收盤 12-24 16:00:00 美东时间
7.67
+0.030
+0.39%
華盛通- 最 高7.91
- 今 開7.64
- 成交量 112.65万股
- 最 低 7.43
- 昨 收 7.64
- 總市值 2.62亿
- 52周最高 9.92
- 市盈率 靜 --
- 換手率 3.30%
- 52周最低 4.68
- 委 比 -89.19%
- 總股本 3415.35万
- 歷史最高 14.986
- 量 比 11.74
- 振 幅 6.28%
- 歷史最低 3.255
- 每 手 1
- 風險率 1.20%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Pedmark Delivers In Japan Study — Less Hearing Loss, Same Cancer-Fighting Power
Pedmark cut cisplatin-related hearing loss in a Japan trial, with strong safety and no impact on tumor response, supporting plans for Japan registration.
12-03 00:56
Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference
Fennec Pharmaceuticals Inc. announced its participation in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, at 1:00 p.m. ET, available via webcast. The webcast can be accessed through the company's investor website, and an archived replay will be provided post-event. Fennec, focused on reducing ototoxicity in cancer patients receiving cisplatin-based chemotherapy, markets PEDMARK, approved in the U.S., E...
11-26 10:59
Fennec Pharmaceuticals Announces Completion Of Full Debt Redemption
Fennec Pharmaceuticals has repurchased and redeemed all outstanding convertible notes issued to Petrichor funds, totaling $21.73 million, eliminating its debt. The company focuses on PEDMARK® and PEDMARQSI®, which have received regulatory approvals in the U.S., Europe, and the UK. PEDMARQSI® is now available in the UK and Germany under a licensing agreement with Norgine. The products benefit from orphan drug exclusivity and pediatric marketing au...
11-19 12:03
Fennec Pharmaceuticals Reports Increased PEDMARK Sales
Fennec Pharmaceuticals ( ($FENC) ) has released its Q3 earnings. Here is a brea...
11-18 11:53
Fennec Pharmaceuticals Q3 EPS $(0.02), Inline, Sales $12.462M Beat $11.257M Estimate
Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly losses of $(0.02) per share which met the analyst consensus estimate. This is a 90.48 percent increase over losses of $(0.21) per share from the same period last
11-14 06:32
Fennec Pharmaceuticals Plans To Launch Common Stock Offering; Terms Not Disclosed
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) ("Fennec" or the "Company"), a specialty pharmaceutical company, today announced that it intends to offer and sell its common shares in an underwritten registered
11-14 05:09
HC Wainwright & Co. Reiterates Buy on Fennec Pharmaceuticals, Maintains $13 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and maintains $13 price target.
08-21 22:36
美股大行评级 | Macquarie维持小鹏汽车"跑赢大市"评级，目标价升至25美元
今日重点评级关注：HC Wainwright & Co.：维持BioXcel Therapeutics"买入"评级，目标价从8美元升至10美元；Craig-Hallum：维持Fennec Pharmaceuticals"买入"评级，目标价从13美元升至14美元
08-18 10:22
Fennec Pharmaceuticals shares are trading lower following a Q2 EPS miss.
Fennec Pharmaceuticals shares are trading lower following a Q2 EPS miss.
08-15 00:35
Fennec Pharmaceuticals Q2 EPS $(0.11) Misses $(0.04) Estimate, Sales $9.65M Beat $9.52M Estimate
Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.04) by 205.56 percent. This is a 45 percent increase over losses of $(0.20) per share
08-14 18:09
